A5101894630- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Cervical Cancer and HPV Research
- Colorectal and Anal Carcinomas
- Uterine Myomas and Treatments
- Endometriosis Research and Treatment
- Management of metastatic bone disease
- Cancer Cells and Metastasis
- Health Systems, Economic Evaluations, Quality of Life
- Intraperitoneal and Appendiceal Malignancies
- Cancer Risks and Factors
- Palliative Care and End-of-Life Issues
- Cancer Treatment and Pharmacology
- Cancer survivorship and care
- Economic and Financial Impacts of Cancer
- Cancer Genomics and Diagnostics
- Renal Diseases and Glomerulopathies
- Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Chemotherapy-related skin toxicity
- Advances in Oncology and Radiotherapy
- Sarcoma Diagnosis and Treatment
- Statistical Methods in Clinical Trials
- Family and Patient Care in Intensive Care Units
- Evaluation and Performance Assessment
Franciscan Health Indianapolis
2011-2023
Trinity College Dublin
2019-2022
Stanford University
2013-2019
Gynecologic Oncology Group
2003-2019
Horizon Health Network
2018
University of Washington
2017
VA Palo Alto Health Care System
2017
Indiana University School of Medicine
1998-2016
Indiana University – Purdue University Indianapolis
2002-2016
Indiana University
2004-2016
To determine whether cisplatin plus paclitaxel (C+P) improved response rate, progression-free survival (PFS), or compared with alone in patients stage IVB, recurrent, persistent squamous cell carcinoma of the cervix. PATIENTS AND METHODS Eligible: measurable disease, performance status (PS) 0 to 2, and adequate hematologic, hepatic, renal function received either 50 mg/m2 C+P (cisplatin 135 mg/m2) every 3 weeks for six cycles. Tumor measurements quality-of-life (QOL) assessments were...
We evaluated the effect of adding secondary cytoreductive surgery to postoperative chemotherapy on progression-free survival and overall among patients who had advanced ovarian cancer residual tumor exceeding 1 cm in diameter after primary surgery.
PURPOSE Taxol (paclitaxel; Bristol-Myers Squibb, Princeton, NJ) is a new antineoplastic drug with broad-spectrum activity in solid tumors, including epithelial ovarian cancer, head and neck esophageal breast bladder lung cancer. Its unique mechanism of action, polymerization tubulin monomers, has stimulated both clinical preclinical research on this agent. As limited supplies became more plentiful, phase II trial was initiated patients advanced squamous cervix cancer who had received no...
Concurrent chemoradiotherapy is the standard of care for locally advanced cervix cancer; optimal chemotherapy regimen not yet defined. This trial was designed to compare outcome protracted venous infusion (PVI) fluorouracil (FU) with weekly cisplatin and concurrent radiation therapy (RT).Patients stage IIB, IIIB, IVA cervical cancer clinically negative aortic nodes were eligible. Pelvic RT dose 45 Gy a parametrial boost involved sides 5.4 9 Gy, high- or low-dose rate intracavitary...
To compare disease progression and mortality between women men infected with human immunodeficiency virus (HIV).Multicenter cohort.Seventeen community-based centers participating in the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).A total of 768 3779 enrolled one or more 11 protocols September 7, 1990, 30, 1993.Survival opportunistic events.The median CD4+ cell count at enrollment into cohort was 0.240 x 10(9)/L (240/microL) 0.137 (P < .001). Compared men, were...
To evaluate the efficacy of cisplatin-based combination chemotherapy in patients with advanced ovarian germ-cell tumors.Nonrandom prospective trial endpoints tumor response, results repeat surgical exploration, progression-free interval, and survival.Cooperative university-based cancer study comprising 27 participating institutions.Ninety-seven were treated all evaluable. Of these, 8 had dysgerminoma 89 other cell types.Patients received 3 to 4 courses cisplatin. vinblastine, bleomycin...
To evaluate the feasibility of sentinel node staging for detection occult regional lymph metastasis in high-risk cutaneous nonmelanoma malignancies.Consecutive clinical case series.Referral university medical center.A consecutive sample patients with a variety malignancies without evidence metastases.Sentinel biopsies were performed using preoperative lymphoscintigraphy, blue dye, and intraoperative radiolocalization.Sensitivity, determined by comparing results biopsy specimen evaluation...
In the randomized phase III trial, Gynecologic Oncology Group (GOG) protocol 240, incorporation of bevacizumab with chemotherapy significantly increased overall survival (OS) in women advanced cervical cancer. A major objective GOG-240 was to prospectively analyze previously identified pooled clinical prognostic factors known as Moore criteria.Potential negative included black race, performance status 1, pelvic disease, prior cisplatin, and progression-free interval <365 days. Risk...
Cancer is a leading cause of death in the United States. Although treatments have improved, patients and caregivers continue to report significant gaps their care. The objective this study was examine views on experiences with current cancer care delivery identify key strategies improve care.Semistructured interviews were conducted 75 45 across recorded, transcribed, analyzed using constant comparative method qualitative analysis.Participants reported multiple delivery, including barriers...
To determine whether a non‑platinum chemotherapy doublet improves overall survival (OS) among patients with recurrent/metastatic cervical carcinoma.Gynecologic Oncology Group protocol 240 is phase 3, randomized, open-label, clinical trial that studied the efficacy of paclitaxel 175 mg/m2 plus topotecan 0.75 days 1-3 (n = 223) vs cisplatin 50 135 or 229), in 452 cancer. Each was also and without bevacizumab (15 mg/kg). Cycles were repeated every 21 until progression, unacceptable toxicity,...